

CLAIM AMENDMENTS

1-42. (Canceled)

43. (Currently Amended) A method of modulating growth of tumor cells *in vivo* in a subject comprising the step of administering to the subject an effective amount of ~~a the~~ composition of ~~claim 37~~ comprising an antibody that binds to Cripto and a pharmaceutically acceptable carrier.

44. (Previously Presented) The method according to claim 43, wherein the subject is human.

45. (Currently Amended) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to ~~said the~~ subject ~~a the~~ composition of ~~claim 37~~ comprising an antibody that binds to Cripto and a pharmaceutically acceptable carrier in an effective amount.

46. (Currently Amended) A method of treating a subject patient having a tumor that over-expresses Cripto comprising administering to ~~said the subject patient a the~~ composition of ~~claim 39~~ comprising an antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 in an effective amount.

47. (Currently Amended) A method of treating a subject patient having a tumor that over-expresses Cripto comprising administering to ~~said the subject patient a the~~ composition of ~~claim 40~~ comprising an antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID No:1 or SEQ ID NO:2 in an effective amount.

48. **(Currently Amended)** A method of treating a subject patient having a tumor that over-expresses Cripto comprising administering to ~~said the subject patient~~ a the composition of claim 41 comprising an antibody which binds specifically to an epitope selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, A7H1.19, A8F1.30, A8G3.5, A19A10.30, A10B2.18, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, B3F6.17, and B11H8.4 bind in an effective amount.

49. **(Canceled)**

50. **(Previously Presented)** The method according to claim 43, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

51-57. **(Canceled)**

58. **(Currently Amended)** The method of claim 43, wherein the antibody is a antibody ~~of claim 1 wherein the antibody is monoclonal~~ antibody antibodies.

59. **(Currently Amended)** The method of claim 43, wherein the antibody is a antibody ~~of claim 1 wherein the antibody is humanized~~ antibody antibodies.

60. **(Currently Amended)** The method of claim 43, wherein the antibody is a antibody ~~of claim 1 wherein the antibody is human~~ antibody antibodies.

61. **Canceled.**

62. **(New)** The method of claim 43, wherein the antibody specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2.

63. (New) The method of claim 43, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')₂ fragment.

64. (New) The method of claim 43, wherein the antibody is a full length antibody.

65. (New) The method of claim 43, wherein the antibody is a single chain antibody.

66. (New) The method of claim 43, wherein the antibody is conjugated to a chemotherapeutic agent.

67. (New) The method of claim 43, wherein the antibody is administered in combination with a nonconjugated chemotherapeutic.

68. (New) The method of claim 66, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

69. (New) The antibody of claim 68, wherein the agent is a maytansinoid.

70. (New) The method of claim 43 wherein the antibody specifically binds to an epitope comprised in the domain spanning amino acid residues from about amino acid 46-62 of SEQ ID NO:1 or 2 which antibody or fragment is conjugated to a maytansinoid and a pharmaceutically acceptable carrier.

71. (New) The method of claim 43, wherein the antibody is a humanized version of the antibody produced by the hybridoma B3F6.17.

72. (New) The method of claim 43, wherein the antibody binds an epitope selected from the group of epitopes to which antibodies produced by hybridomas selected from the group consisting of A10B2.18 and B3F6.17 bind.

73. (New) The method of claim 43, wherein the antibody specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 which is capable of internalizing Cripto.

74. (New) The method of claim 43, wherein the antibody specifically binds to an epitope comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID NO:1 or SEQ ID NO:2.

75. (New) The method of claim 43, wherein the antibody binds an epitope selected from the group of epitopes to which antibodies produced by hybridomas selected from the group consisting of A6.C12.11, A8G3.5, and A6F8.6 bind.

76. (New) The method of claim 43, wherein the antibody specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 which inhibits the interaction of Cripto and ALK4.

77. (New) The method of claim 43, wherein the antibody binds specifically to an epitope selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, A7H1.19, A8F1.30, A8G3.5, A19A10.30, A10B2.18, A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14, A17A2.16, A17C12.28, A17G12.1, A17H6.1, A18B3.11, B3F6.17, and B11H8.4 bind.

78. (New) The method of claim 43, wherein the antibody binds to an epitope comprised in the domain spanning amino acid residues 77-111 of SEQ ID NO:1 or SEQ ID NO:2.